Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease.
Matthieu F. Bastide
(1)
,
Wassilios G. Meissner
(1)
,
Barbara Picconi
(2)
,
Stefania Fasano
(3)
,
Pierre-Olivier Fernagut
(1)
,
Michael Feyder
(4)
,
Veronica Francardo
(5)
,
Cristina Alcacer
(5)
,
Yuchuan Ding
(6)
,
Ricardo Brambilla
(3)
,
Gilberto Fisone
(4)
,
Stoessl Jon
(7)
,
Mathieu Bourdenx
(1)
,
Michael Engeln
(1)
,
Sylvia Navailles
(1)
,
Philippe de Deurwaerdere
(1)
,
Kin Ko Way
(1)
,
Nicola Simola
(8)
,
Micacla Morelli
(9)
,
Laurent Groc
(10)
,
Maria Cruz Rodriguez
(11)
,
Eugenia Vselvolod Gurevich
(12)
,
Michael Quik
(13)
,
Michele Morari
(14)
,
Manuela Mellone
(15)
,
Fabrizio Gardoni
(15)
,
Elisabetta Tronci
(9)
,
Alan R Crossman
(16)
,
Un Jung Kang
(5)
,
Kathy Steece-Collier
(17)
,
Susan H. Fox
(18)
,
Mauro Carta
(9)
,
M Angela Cenci
(19)
,
Erwan Bezard
(1)
1
IMN -
Institut des Maladies Neurodégénératives [Bordeaux]
2 Laboratory of Neurophysiology and Plasticity
3 Division of Neuroscience
4 Department of Neuroscience Stockholm
5 Basal Ganglia Pathophysiology Unit
6 Department of Neurology
7 UBC - University of British Columbia
8 Pacific Parkinson's Research Centre
9 Department of Biomedical Sciences
10 IINS - Interdisciplinary Institute for Neuroscience [Bordeaux]
11 Deparment of Neurology
12 Department of Pharmacology
13 Center of Health Science
14 Department of Medical Sciences
15 Dipartimento di Scienze Farmacologiche e Biomolecolari
16 Motac Neuroscience
17 Department of Translational Science and Molecular Medicine
18 Toronto Western Research Institute
19 Basal Ganglia Pathophysiology Unit
2 Laboratory of Neurophysiology and Plasticity
3 Division of Neuroscience
4 Department of Neuroscience Stockholm
5 Basal Ganglia Pathophysiology Unit
6 Department of Neurology
7 UBC - University of British Columbia
8 Pacific Parkinson's Research Centre
9 Department of Biomedical Sciences
10 IINS - Interdisciplinary Institute for Neuroscience [Bordeaux]
11 Deparment of Neurology
12 Department of Pharmacology
13 Center of Health Science
14 Department of Medical Sciences
15 Dipartimento di Scienze Farmacologiche e Biomolecolari
16 Motac Neuroscience
17 Department of Translational Science and Molecular Medicine
18 Toronto Western Research Institute
19 Basal Ganglia Pathophysiology Unit
Wassilios G. Meissner
- Fonction : Auteur
- PersonId : 930251
Pierre-Olivier Fernagut
- Fonction : Auteur
- PersonId : 958962
- IdHAL : pierre-olivier-fernagut
Mathieu Bourdenx
- Fonction : Auteur
- PersonId : 772057
- ORCID : 0000-0002-9799-9222
- IdRef : 190626291
Laurent Groc
- Fonction : Auteur
- PersonId : 958886
Erwan Bezard
- Fonction : Auteur
- PersonId : 873067
Résumé
Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa (L-dopa) therapy for Parkinson's disease (PD). L-dopa-induced dyskinesia (LID) are ultimately experienced by the vast majority of patients. In addition, psychiatric conditions often manifested as compulsive behaviours, are emerging as a serious problem in the management of L-dopa therapy. The present review attempts to provide an overview of our current understanding of dyskinesia and other L-dopa-induced dysfunctions, a field that dramatically evolved in the past twenty years. In view of the extensive literature on LID, there appeared a critical need to re-frame the concepts, to highlight the most suitable models, to review the central nervous system (CNS) circuitry that may be involved, and to propose a pathophysiological framework was timely and necessary. An updated review to clarify our understanding of LID and other L-dopa-related side effects was therefore timely and necessary. This review should help in the development of novel therapeutic strategies aimed at preventing the generation of dyskinetic symptoms.